MIRM · NASDAQ · STOCK
Mirum Pharmaceuticals (MIRM) Stock Analysis
$82.45
52W $63.23 – $130.00
55/100
$4.86B
-5.5
0.49
Is MIRM Bullish or Bearish?
Mixed.
Innellis AI committee rates Mirum Pharmaceuticals, Inc. (MIRM) Watch with a composite score of 55/100
, based on 6 analysts with 50% agreement.
Last updated October 14, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +4.68 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -15.32 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.53 across 18 articles, 14d). Value Analyst remains cautious — price-to-book of 13.0x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 44.0% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- News sentiment is positive (+0.53 across 18 articles, 14d) — News
Bear Case
- Price-to-book of 13.0x prices in significant intangible value — Value
- ROE of only -289.3% -- cheap may mean cheap for a reason — Value
- 3 consecutive earnings misses -- execution concerns — Growth
- Price structure making lower highs and lower lows — Technical
- Trend and market structure agree -- coherent bearish picture — Technical
- Daily trend (downtrend) conflicts with the weekly trend (uptrend) -- fighting the larger trend — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 14, 2026
Overall Committee Score
55/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 66%
of 192 Healthcare peers
Value Analyst
bearish
30
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 13.0x prices in significant intangible value
Growth Analyst
bullish
63
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 44.0% YoY -- genuine top-line momentum
− 3 consecutive earnings misses -- execution concerns
Technical Analyst
neutral
46
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− Price structure making lower highs and lower lows
Risk Analyst
neutral
52
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
− Bollinger bandwidth of 25.4% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
75
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.53 across 18 articles, 14d)
Portfolio Manager
bearish
35
/ 100 · Low confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− 2 existing position pair(s) are highly correlated already
Investment Thesis Evolution
Committee score moved marginally from 57.8 to 55.3.
- New bearish signals: 1 appeared.
- Bullish support removed: 2 signal(s) disappeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
Analyst-level changes:
- Macro Analyst: score 80->65 (-15).
- News Analyst: +1 bullish signal(s).
- Portfolio Manager: score 30->35 (+5).
- Risk Analyst: +1 bearish signal(s).
Comparing 2026-10-13 to 2026-10-14 (1 day apart).
Technical Analysis
RSI (14)
33.5
Neutral
MACD Histogram
0.022
Bullish Momentum
Trend Direction
Downtrend
Weekly: Uptrend
Market Structure
Lh Ll
Support
$63.34
Resistance
$109.00
Bollinger %B
0.20
Inside Bands
Price vs Moving Averages
EMA 9
$82.75
Below
EMA 21
$86.36
Below
EMA 50
$92.85
Below
EMA 200
$93.81
Below
Fundamental Analysis
Valuation
100
Growth
32
Profitability
25
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-5.5×
P/B Ratio
—
PEG Ratio
0.00
Dividend Yield
0.00%
52W High
$130.00
52W Low
$63.23
Quality & Growth
ROE
-742.4%
ROA
-277.2%
Gross Margin
8170.1%
Operating Margin
-1741.9%
Revenue Growth YoY
—
Debt / Equity
—
AI Fundamental Assessment
P/E ratio of -5.5 (inexpensive relative to a 15-40x range); Price-to-book of -484.2x; PEG ratio of 0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -7.4%; Return on assets of -2.8%; Net margin of -139.2%; Gross margin of 81.7%; Current ratio of 2.86 (healthy short-term liquidity); Debt-to-equity of -72.97; Free cash flow per share is negative (-7.23); Most recent quarter missed estimates by 52.6%; 3 consecutive earnings misses; EPS growth accelerating (-980.0% -> +1.9% QoQ); Analyst estimates falling over recent quarters
Get the Full MIRM Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →